Markus B Funk1, Margarethe Heiden2, Peter Volkers3, Annette Lohmann1, Brigitte Keller-Stanislawski1. 1. Division of Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Langen, Germany. 2. Division of Transfusion Medicine, Paul-Ehrlich-Institut, Langen, Germany. 3. Section of Biostatistics, Paul-Ehrlich-Institut, Langen, Germany.
Abstract
BACKGROUND: To assess the impact of safety measures, we compared reporting rates of transfusion-related reactions before and after the implementation of six measures in 1999, 2004, 2006, 2008 and 2009. METHODS: Reporting rates of transfusion-transmitted bacterial infection (TTBI), viral infection (TTVI) and immune-mediated transfusion-related acute lung injury (TRALI) were calculated on the basis of confirmed annual reports and distributed blood components. RESULTS: The introduction of HCV NAT testing caused a significant reduction of HCV reporting rate from 1:0.6 to 1:83.16 million administered blood components (p < 0.0001), donor screening for antibodies to hepatitis B core antigen caused a reduction of HBV reporting rate from 1:2.90 to 1:10.70 million units (p = 0.0168). A significant reduction from 1:0.094 to 1:2.42 million fresh frozen plasma (FFP) units could also be achieved by risk minimisation TRALI measures (p < 0.0001). Implementation of pre-donation sampling did not result in a significant decrease in TTBI, whereas limitation of shelf life for platelet concentrate (PC) minimised the TTBI reporting rate from 1:0.088 to 1:0.19 million PC units (p = 0.041). For HIV NAT pool testing, no significant reduction in HIV transmission was found due to very low reporting rates (1:10 million versus 1:27 million blood components, p = 0.422). CONCLUSION: On the basis of haemovigilance data, a significant benefit could be demonstrated for four of six implemented safety measures.
BACKGROUND: To assess the impact of safety measures, we compared reporting rates of transfusion-related reactions before and after the implementation of six measures in 1999, 2004, 2006, 2008 and 2009. METHODS: Reporting rates of transfusion-transmitted bacterial infection (TTBI), viral infection (TTVI) and immune-mediated transfusion-related acute lung injury (TRALI) were calculated on the basis of confirmed annual reports and distributed blood components. RESULTS: The introduction of HCV NAT testing caused a significant reduction of HCV reporting rate from 1:0.6 to 1:83.16 million administered blood components (p < 0.0001), donor screening for antibodies to hepatitis B core antigen caused a reduction of HBV reporting rate from 1:2.90 to 1:10.70 million units (p = 0.0168). A significant reduction from 1:0.094 to 1:2.42 million fresh frozen plasma (FFP) units could also be achieved by risk minimisation TRALI measures (p < 0.0001). Implementation of pre-donation sampling did not result in a significant decrease in TTBI, whereas limitation of shelf life for platelet concentrate (PC) minimised the TTBI reporting rate from 1:0.088 to 1:0.19 million PC units (p = 0.041). For HIV NAT pool testing, no significant reduction in HIV transmission was found due to very low reporting rates (1:10 million versus 1:27 million blood components, p = 0.422). CONCLUSION: On the basis of haemovigilance data, a significant benefit could be demonstrated for four of six implemented safety measures.
Authors: Steven Kleinman; Tim Caulfield; Penny Chan; Robertson Davenport; Janice McFarland; Susan McPhedran; Maureen Meade; Douglas Morrison; Thomas Pinsent; Pierre Robillard; Peter Slinger Journal: Transfusion Date: 2004-12 Impact factor: 3.157
Authors: Dirk de Korte; Joyce Curvers; Wim L A M de Kort; Tiny Hoekstra; Cees L van der Poel; Erik A M Beckers; Jan H Marcelis Journal: Transfusion Date: 2006-03 Impact factor: 3.157
Authors: G Walther-Wenke; C H Wirsing von König; W Däubener; M Heiden; J Hoch; B Hornei; P Volkers Journal: Vox Sang Date: 2010-10-28 Impact factor: 2.144
Authors: C Micha Nübling; Margarethe Heiden; Michael Chudy; Julia Kress; Rainer Seitz; Brigitte Keller-Stanislawski; Markus B Funk Journal: Transfusion Date: 2009-05-14 Impact factor: 3.157
Authors: Giovanni Di Minno; David Navarro; Carlo Federico Perno; Mariana Canaro; Lutz Gürtler; James W Ironside; Hermann Eichler; Andreas Tiede Journal: Ann Hematol Date: 2017-06-18 Impact factor: 3.673